Castle Biosciences (CSTL) announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cutaneous Melanoma: An Expert Consensus Panel,” which endorses the Company’s DecisionDx-Melanoma test. “This consensus translates the robust data supporting DecisionDx-Melanoma into practical direction for clinicians,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “The panel’s unanimous endorsement of DecisionDx-Melanoma underscores its value in supporting informed, personalized care decisions that may help improve outcomes for patients with melanoma.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences announces new data on DecisionDx-Melanoma test
- Castle Biosciences: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Castle Biosciences Navigates Regulatory Uncertainty Amid Shifting Policies and Trade Challenges
- Castle Biosciences’ Earnings Call Highlights Growth and Challenges
- Castle Biosciences price target raised to $41 from $39 at Baird